Literature DB >> 24710899

In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.

Sang-Bum Kim1, In-Soo Yoon2, Kyu-Sang Kim1, Sung-Jun Cho1, Yeong Shik Kim3, Hyun-Jong Cho4, Suk-Jae Chung1, Saeho Chong1, Dae-Duk Kim1.   

Abstract

Puerarin (8-β-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) is a major pharmacological component of Puerariae Radix, the root of Pueraria lobata. We investigated the effect of puerarin on hepatic cytochrome P450-mediated drug metabolism in rats and humans. The in vitro cytochrome P450 inhibitory effect of puerarin in human and rat liver microsomes was evaluated using the following model cytochrome P450 substrates: phenacetin for CYP1A, diclofenac for CYP2C, dextromethorphan for CYP2D, and testosterone for CYP3A. The in vivo pharmacokinetics of intravenous and oral buspirone, a probe substrate for CYP3A, was studied with single simultaneous intravenous coadministration of puerarin in rats. In the in vitro cytochrome P450 inhibition study, the rate of disappearance of testosterone was significantly reduced in the presence of 10 µM PU, while that of other cytochrome P450 substrates was not significantly affected in both human and rat liver microsomes, suggesting that puerarin inhibits the in vitro hepatic CYP3A-mediated metabolism in the human and rat systems (IC50 = 15.5 ± 3.9 µM). After intravenous administration of buspirone with single simultaneous coadministration of intravenous puerarin at a dose of 10 mg/kg in rats, the total area under the plasma concentration-time curve from time zero to time infinity was increased while time-averaged total body clearance decreased. When buspirone was orally administered in rats with the 10 mg/kg intravenous puerarin coadministration, both total area under the plasma concentration-time curve from time zero to time infinity and the extent of absolute oral bioavailability were significantly increased. Therefore, results of the in vitro microsomal and in vivo pharmacokinetic studies suggest the possible inhibition of hepatic CYP3A-mediated drug metabolism by puerarin administration, potentially leading to metabolism-mediated herb-drug interactions with clinical significance. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24710899     DOI: 10.1055/s-0034-1368350

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  6 in total

1.  Puerarin inhibits proliferation and induces apoptosis in human glioblastoma cell lines.

Authors:  Ji-An Yang; Ji-Qiang Li; Ling-Min Shao; Qian Yang; Bao-Hui Liu; Ting-Feng Wu; Peng Wu; Wei Yi; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.

Authors:  Hyun-Jong Cho; In-Soo Yoon
Journal:  Evid Based Complement Alternat Med       Date:  2015-01-06       Impact factor: 2.629

3.  Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague-dawley Rats.

Authors:  Sang-Bum Kim; Seung-Sik Cho; Hyun-Jong Cho; In-Soo Yoon
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

Review 4.  Cytochrome P450 and P-Glycoprotein-Mediated Interactions Involving African Herbs Indicated for Common Noncommunicable Diseases.

Authors:  Gregory Ondieki; Makafui Nyagblordzro; Siambi Kikete; Rongjia Liang; Lili Wang; Xin He
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-31       Impact factor: 2.629

5.  Effects of puerarin on the pharmacokinetics of astragaloside IV in rats and its potential mechanism.

Authors:  Huan Zhang; Jiaying Song; Huizhen Dai; Yanchao Liu; Lili Wang
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

6.  Clinical Evaluation of Acetaminophen-Galgeuntang Interaction Based on Population Approaches.

Authors:  Quyen Thi Tran; So Jung Park; Hyun-Moon Back; Lien Thi Ngo; Duc Tuan Cao; Hung Van Nguyen; Sangkeun Jung; Jung-Woo Chae; Yang Chun Park; Hwi-Yeol Yun
Journal:  Pharmaceutics       Date:  2020-12-04       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.